Euro Manganese Inc. — Proxy Solicitation & Information Statement 2021

Apr 6, 2021

==> picture [256 x 87] intentionally omitted <==

EURO MANGANESE INC.

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN (the " Notice ") that a special meeting (the " Meeting ") of holders (the " Shareholders ") of common shares (including common shares held as CHESS Depositary Interests) of Euro Manganese Inc. ARBN 627 968 567 (the " Corporation ") will be held at the offices of Stikeman Elliott LLP at 1700 - 666 Burrard Street, Vancouver, British Columbia, V6C 2X8 , on Wednesday, May 5, 2021 , at 10:00 a.m. (Vancouver time).

The Meeting is being convened for the Corporation to seek Shareholder approval as required under the rules of the Australian Securities Exchange (" ASX ") with respect to the issuance by the Corporation of common shares of the Corporation (" Shares ") and/or 50,000,000 CHESS Depositary Interests (" CDIs "), with each CDI representing one Share as part of a private placement (the " Offering ") of 50,000,000 CDIs, at a price of A$0.60 per CDI (approximately C$0.58 per Share), to sophisticated and professional investors, for aggregate gross proceeds of A$30.0 million (approximately C$29.0 million), all as more particularly described in this Notice. The Offering was announced by the Corporation on March 22, 2021, and is more particularly described in the management information circular of the Corporation dated March 24, 2021 (the " Circular ") accompanying this Notice.

The Offering is being conducted in two tranches:

• a first placement comprised of 41,666,666 CDIs for aggregate gross proceeds of A$25.0 million (approximately C$24.2 million) which is anticipated to complete on or about March 30, 2021 (the " Tranche 1 Placement "); and

• a subsequent placement of an additional 8,333,334 CDIs for aggregate gross proceeds of A$5.0 million (approximately C$4.8 million) which, subject to receipt of Shareholder approval being sought at the Meeting, is anticipated to complete on or about May 10, 2021 (" Tranche 2 Placement ").

The CDIs to be issued under the Tranche 2 Placement, as described in Resolution 2 below, are subscribed for on identical terms to the CDIs issued under the Tranche 1 Placement. Net proceeds of the Offering will be used by the Corporation to advance its Chvaletice Manganese Project in the Czech Republic (the " Project "), including completing the installation and commissioning of the Corporation's high-purity manganese demonstration plant, the initial year of operation of the demonstration plant, completing the

1

Project's permitting and feasibility study, for certain scheduled land acquisition payments and for other general corporate purposes.

As part of the compensation to be paid to the lead manager, Canaccord Genuity (Australia) Limited (" Canaccord Genuity "), in connection with the Offering, the Corporation has agreed, subject to Shareholder approval, to issue Canaccord Genuity 2,500,000 broker warrants (" Broker Warrants ") exercisable any time prior to the date that is 24 months from the closing of the Tranche 2 Placement, with an exercise price of C$0.58 per Share.

The resolutions to be considered at this Meeting relate to obtaining Shareholder approval under ASX Listing Rules 7.1 and 7.4 for the issuance of CDIs under the Offering and under ASX Listing Rule 7.1 for the issuance of the Broker Warrants to Canaccord Genuity in connection with the Offering. Details of the resolutions to be considered at the Meeting are set out in the Circular accompanying this Notice.

The Meeting is being called to consider the following formal business matters:

Resolution 1 - Ratification of issue of Shares and CDIs under the Tranche 1 Placement

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

That, for the purpose of ASX Listing Rule 7.4 and for all other purposes, the issue of 41,666,666 fully paid CDIs at subscription prices of A$0.60 per CDI, to sophisticated and professional investors under the Tranche 1 Placement, as described in the Circular accompanying this Notice, be ratified and approved.

Resolution 2 - Approval of issue of Shares and CDIs under the Tranche 2 Placement

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

That, for the purpose of ASX Listing Rule 7.1 and for all other purposes, the issue of 8,333,334 fully paid CDIs at a subscription price of A$0.60 per CDI, to sophisticated and professional investors under the Tranche 2 Placement, on the terms and conditions described in the Circular accompanying this Notice, is approved.

Resolution 3 - Approval of issue of 2,500,000 Broker Warrants to Canaccord Genuity as Compensation as Lead Manager for the Offering

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, the issue of 2,500,000 Broker Warrants to Canaccord Genuity (Australia) Limited, exercisable any time prior to the date that is 24 months from the closing of the Tranche 2 Placement having an exercise price of C$0.58 per Share, on the terms and conditions described in the Circular accompanying this Notice, is approved.

Other Business. Shareholders may be asked to consider and transact such other matters that may be brought before the Meeting.

While as of the date of this Circular, we are intending to hold the Meeting in physical face to face format, we are continuously monitoring the current coronavirus (COVID-19) outbreak. In light of the rapidly

2

evolving news and guidelines related to COVID-19, we ask that, in considering whether to attend the Meeting in person, shareholders follow, among other things, the instructions of the Public Health Agency of Canada (https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid19.html) and any applicable additional provincial and local instructions. You should not attend the Meeting in person if you are experiencing any cold or flu-like symptoms, or if you or someone with whom you have been in close contact has travelled to/from outside of Canada within the 14 days prior to the Meeting. All shareholders are strongly encouraged to vote prior to the Meeting by any of the means described on pages 3 and 4 of the Circular accompanying this Notice.

We reserve the right to take any additional precautionary measures we deem appropriate in relation to the Meeting in response to further developments in respect of the COVID-19 outbreak including, if we consider necessary or advisable, providing a webcast version of the Meeting and/or hosting the Meeting solely by means of remote communication. Changes to the Meeting date and/or means of holding the Meeting will be announced by way of press release and placed on the ASX. Please monitor our press releases as well as our website at www.mn25.ca for updated information. We advise you to check our website one week prior to the Meeting date for the most current information. We do not intend to prepare or mail an amended Circular in the event of changes to the Meeting format.

Website Where Meeting Materials are Posted

The Circular may be viewed online via the System for Electronic Document Analysis and Retrieval at www.sedar.com or on the Corporation's website at www.mn25.ca.

Obtaining Paper Copies of Materials

Shareholders may also obtain paper copies of the Circular free of charge upon request to the Corporation's Corporate Secretary at 1500 - 1040 West Georgia Street, Vancouver, British Columbia V6E 4H8, or by phone at 604-681-1010.

A request for paper copies which are required in advance of the Meeting should be sent so that they are received by the Corporation by April 28, 2021 to allow sufficient time for Shareholders to receive the paper copies and to return their proxies or voting instruction forms to Intermediaries not later than 48 hours (excluding Saturdays, Sundays and statutory holidays in the City of Vancouver, British Columbia) prior to the time set for the Meeting or any adjournments or postponements thereof.

Voting

The board of directors of the Corporation has fixed the close of business on March 24, 2021 as the record date (the " Record Date ") for the purpose of determining Shareholders entitled to receive notice of, and vote at, the Meeting. The failure of any Shareholder to receive notice of the Meeting does not deprive such Shareholder of the right to vote at the Meeting. Only Shareholders of record at the close of business on the Record Date are entitled to vote at the Meeting.

All Shareholders are invited to attend the Meeting and may attend in person or may be represented by proxy. However, a "beneficial" or "non-registered" Shareholder will not be recognized directly at the Meeting for the purposes of voting common shares registered in the name of his/her/its broker. Instead, a beneficial Shareholder may attend the Meeting as proxyholder for a registered Shareholder and vote the common shares in that capacity.

3

Only Shareholders as of the Record Date are entitled to receive notice of and vote at the Meeting. Shareholders who are unable to attend the Meeting in person, or any adjournments or postponements thereof, are requested to complete, date and sign the form of proxy (registered holders) or voting instruction form (beneficial holders).

SHAREHOLDERS ARE REMINDED TO REVIEW THE CIRCULAR BEFORE VOTING.

Dated at Vancouver, British Columbia this 24th day of March 2021.

BY ORDER OF THE BOARD OF DIRECTORS

(Signed) " John Webster " Chairman

4